|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 16.05 0.00 0.00%
Ms. Adine Grate Axen was Independent Member of the Board of Directors of Swedish Orphan Biovitrum AB since April 27 2010. She also serves as Member of the Company Audit Committee. Prior to this she was Member of the Advisory Committee for the Sale of Stateowned Companies Board member of Gambro AB and OMX AB . She held various senior management positions and Board assignments within Investor AB and was member of the management group . She was also Board member of Acne Studios Holding AB Micaro AB Evry AS EDB Ergo Group AS and Carnegie Investment Bank AB. She serves as Chairman of Nasdaq OMX Stockholms Listing Committee and Vice Chairman of the Seventh AP Fund as well as Board member of Sky Ltd Sampo OY HI3GS Holding AB 3GIS Infrastructure Services AB HI3G Denmark ApS Madrague AB and Swedavia AB. She holds a MS degree from Handelshogskolan i Stockholm and has completed Advanced Management Program at Harvard.
Age: 54 Director Since 2010
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 8.0 %
which means that it generated profit of $8.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 5.6 %
meaning that it generated $5.6 on every $100 dollars invested by stockholders.
The company has accumulated 53.55 M in total debt with debt to equity ratio (D/E) of 0.09 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.74 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.